179 related articles for article (PubMed ID: 33627380)
1. Hepatobiliary Cancer Risk in Patients with Inflammatory Bowel Disease: A Scandinavian Population-Based Cohort Study.
Erichsen R; Olén O; Sachs MC; Pedersen L; Halfvarson J; Askling J; Ekbom A; Ludvigsson JF; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):886-894. PubMed ID: 33627380
[TBL] [Abstract][Full Text] [Related]
2. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
Franceschet I; Cazzagon N; Del Ross T; D'Incà R; Buja A; Floreani A
Eur J Gastroenterol Hepatol; 2016 May; 28(5):508-13. PubMed ID: 26872110
[TBL] [Abstract][Full Text] [Related]
3. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States.
Altekruse SF; Petrick JL; Rolin AI; Cuccinelli JE; Zou Z; Tatalovich Z; McGlynn KA
PLoS One; 2015; 10(3):e0120574. PubMed ID: 25837669
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory bowel disease and risk of cholangiocarcinoma: evidence from a meta-analysis of population-based studies.
Huai JP; Ding J; Ye XH; Chen YP
Asian Pac J Cancer Prev; 2014; 15(8):3477-82. PubMed ID: 24870743
[TBL] [Abstract][Full Text] [Related]
5. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
Weismüller TJ; Trivedi PJ; Bergquist A; Imam M; Lenzen H; Ponsioen CY; Holm K; Gotthardt D; Färkkilä MA; Marschall HU; Thorburn D; Weersma RK; Fevery J; Mueller T; Chazouillères O; Schulze K; Lazaridis KN; Almer S; Pereira SP; Levy C; Mason A; Naess S; Bowlus CL; Floreani A; Halilbasic E; Yimam KK; Milkiewicz P; Beuers U; Huynh DK; Pares A; Manser CN; Dalekos GN; Eksteen B; Invernizzi P; Berg CP; Kirchner GI; Sarrazin C; Zimmer V; Fabris L; Braun F; Marzioni M; Juran BD; Said K; Rupp C; Jokelainen K; Benito de Valle M; Saffioti F; Cheung A; Trauner M; Schramm C; Chapman RW; Karlsen TH; Schrumpf E; Strassburg CP; Manns MP; Lindor KD; Hirschfield GM; Hansen BE; Boberg KM;
Gastroenterology; 2017 Jun; 152(8):1975-1984.e8. PubMed ID: 28274849
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study.
Olén O; Erichsen R; Sachs MC; Pedersen L; Halfvarson J; Askling J; Ekbom A; Sørensen HT; Ludvigsson JF
Lancet Gastroenterol Hepatol; 2020 May; 5(5):475-484. PubMed ID: 32066530
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.
Yu J; Refsum E; Helsingen LM; Folseraas T; Ploner A; Wieszczy P; Barua I; Jodal HC; Melum E; Løberg M; Blom J; Bretthauer M; Adami HO; Kalager M; Ye W
United European Gastroenterol J; 2022 Mar; 10(2):212-224. PubMed ID: 35107865
[TBL] [Abstract][Full Text] [Related]
8. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003.
Erichsen R; Jepsen P; Vilstrup H; Ekbom A; Sørensen HT
Eur J Epidemiol; 2009; 24(9):513-20. PubMed ID: 19557525
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.
El-Serag HB; Engels EA; Landgren O; Chiao E; Henderson L; Amaratunge HC; Giordano TP
Hepatology; 2009 Jan; 49(1):116-23. PubMed ID: 19085911
[TBL] [Abstract][Full Text] [Related]
10. Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD.
Fevery J; Van Steenbergen W; Van Pelt J; Laleman W; Hoffman I; Geboes K; Vermeire S; Nevens F
Aliment Pharmacol Ther; 2016 Mar; 43(5):612-20. PubMed ID: 26748470
[TBL] [Abstract][Full Text] [Related]
11. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project.
Petrick JL; Campbell PT; Koshiol J; Thistle JE; Andreotti G; Beane-Freeman LE; Buring JE; Chan AT; Chong DQ; Doody MM; Gapstur SM; Gaziano JM; Giovannucci E; Graubard BI; Lee IM; Liao LM; Linet MS; Palmer JR; Poynter JN; Purdue MP; Robien K; Rosenberg L; Schairer C; Sesso HD; Sinha R; Stampfer MJ; Stefanick M; Wactawski-Wende J; Zhang X; Zeleniuch-Jacquotte A; Freedman ND; McGlynn KA
Br J Cancer; 2018 Apr; 118(7):1005-1012. PubMed ID: 29520041
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.
Welzel TM; Graubard BI; El-Serag HB; Shaib YH; Hsing AW; Davila JA; McGlynn KA
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1221-8. PubMed ID: 17689296
[TBL] [Abstract][Full Text] [Related]
13. Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project.
Petrick JL; Freedman ND; Graubard BI; Sahasrabuddhe VV; Lai GY; Alavanja MC; Beane-Freeman LE; Boggs DA; Buring JE; Chan AT; Chong DQ; Fuchs CS; Gapstur SM; Gaziano JM; Giovannucci EL; Hollenbeck AR; King LY; Koshiol J; Lee IM; Linet MS; Palmer JR; Poynter JN; Purdue MP; Robien K; Schairer C; Sesso HD; Sigurdson AJ; Zeleniuch-Jacquotte A; Wactawski-Wende J; Campbell PT; McGlynn KA
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1398-406. PubMed ID: 26126626
[TBL] [Abstract][Full Text] [Related]
14. NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project.
Petrick JL; Sahasrabuddhe VV; Chan AT; Alavanja MC; Beane-Freeman LE; Buring JE; Chen J; Chong DQ; Freedman ND; Fuchs CS; Gaziano JM; Giovannucci E; Graubard BI; Hollenbeck AR; Hou L; Jacobs EJ; King LY; Koshiol J; Lee IM; Linet MS; Palmer JR; Purdue MP; Rosenberg L; Schairer C; Sesso HD; Sigurdson AJ; Wactawski-Wende J; Zeleniuch-Jacquotte A; Campbell PT; McGlynn KA
Cancer Prev Res (Phila); 2015 Dec; 8(12):1156-62. PubMed ID: 26391917
[TBL] [Abstract][Full Text] [Related]
15. Cancer surveillance in patients with primary sclerosing cholangitis.
Razumilava N; Gores GJ; Lindor KD
Hepatology; 2011 Nov; 54(5):1842-52. PubMed ID: 21793028
[TBL] [Abstract][Full Text] [Related]
16. Cancer risk, screening and surveillance in primary sclerosing cholangitis.
Chascsa DM; Lindor KD
Minerva Gastroenterol Dietol; 2019 Sep; 65(3):214-228. PubMed ID: 31220911
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.
Welzel TM; Graubard BI; Zeuzem S; El-Serag HB; Davila JA; McGlynn KA
Hepatology; 2011 Aug; 54(2):463-71. PubMed ID: 21538440
[TBL] [Abstract][Full Text] [Related]
18. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study.
Kornfeld D; Ekbom A; Ihre T
Scand J Gastroenterol; 1997 Oct; 32(10):1042-5. PubMed ID: 9361178
[TBL] [Abstract][Full Text] [Related]
19. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population-based analysis.
Spolverato G; Bagante F; Tsilimigras D; Ejaz A; Cloyd J; Pawlik TM
J Surg Oncol; 2019 Mar; 119(3):278-287. PubMed ID: 30554420
[TBL] [Abstract][Full Text] [Related]
20. Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the General Population.
Olén O; Askling J; Sachs MC; Frumento P; Neovius M; Smedby KE; Ekbom A; Malmborg P; Ludvigsson JF
Gastroenterology; 2019 Feb; 156(3):614-622. PubMed ID: 30342031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
